The BRAF V600E mutation leads to the continuous activation of the MAPK/ERK signaling pathway, which promotes cell proliferation and survival. Vemurafenib inhibits this mutated BRAF protein, thereby disrupting the aberrant signaling and inducing cancer cell death. This makes it particularly effective in tumors harboring this specific mutation.
